ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,567.19
      1.06%
      US Tech 100
      19,828.00
      0.95%
      Dow Jones
      39,375.87
      0.17%
      Brent Oil
      86.775
      0.00%
      Bitcoin
      57,951.93
      2.30%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Lexicon Pharmaceuticals Inc (LXRX)

      7. Lexicon Pharmaceuticals Inc (LXRX) News

      LXRX

      Lexicon Pharmaceuticals (LXRX)

      Lexicon Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:LXRX
      DateTimeSourceHeadlineSymbolCompany
      06/23/20238:45PMGlobeNewswire Inc.Lexicon Announces Planned Advancement of LX9211 Into Late-Stage DevelopmentNASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/22/20234:02PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/20/20234:31PMEdgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/20/20238:00AMGlobeNewswire Inc.Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific SessionsNASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/15/20235:00PMGlobeNewswire Inc.UPDATE: Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart FailureNASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/06/20234:01PMGlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/06/20236:01AMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/05/20234:01PMGlobeNewswire Inc.Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional SharesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/02/20234:32PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/01/20238:13AMEdgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/01/20238:00AMGlobeNewswire Inc.Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private PlacementNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/31/20234:13PMEdgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/31/20234:01PMGlobeNewswire Inc.Lexicon Announces Proposed Public Offering of Common StockNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/26/20235:25PMDow Jones NewsLexicon Pharmaceuticals Share Up 6.6% as FDA Grants Approval to Heart-Failure Treatment InpefaNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/26/20234:49PMDow Jones NewsLexicon Pharmaceuticals' Heart-Failure Treatment Inpefa Gets FDA ApprovalNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/26/20234:05PMGlobeNewswire Inc.Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart FailureNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/22/20234:08PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/22/20234:07PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/22/20234:06PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/22/20234:06PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/22/20234:05PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/22/20234:04PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/22/20234:02PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/10/20234:30PMGlobeNewswire Inc.New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart FailureNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/02/20234:04PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/02/20234:00PMGlobeNewswire Inc.Lexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/28/20234:44PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/28/20234:41PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/28/20234:35PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/28/20234:32PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:LXRX